FDA Approves DESVENLAFAXINE — Marlex Pharmaceuticals, Inc.

Marlex Pharmaceuticals, Inc. has secured final FDA approval for its desvenlafaxine succinate tablet, marking the company’s second serotonin norepinephrine reuptake inhibitor (SNRI) entry via the 505(b)(2) pathway. This entry into the crowded depression and anxiety market is expected to intensify competition with the current brand leader in an estimated $1 billion market segment.